J S Guimbellot1, A Baines2, A Paynter2, S L Heltshe3, J VanDalfsen2, M Jain4, S M Rowe5, S D Sagel6. 1. Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham (UAB), Birmingham, AL, United States; Department of Pediatrics, Division of Pulmonary and Sleep Medicine, UAB, Birmingham, AL, United States. Electronic address: jguimbellot@peds.uab.edu. 2. CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, United States. 3. CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, United States; Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington, Seattle WA, United States. 4. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. 5. Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham (UAB), Birmingham, AL, United States; Department of Pediatrics, Division of Pulmonary and Sleep Medicine, UAB, Birmingham, AL, United States; Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine; and Department of Cell Developmental and Integrative Biology, UAB, Birmingham, AL, United States. 6. Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Abstract
BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, ivacaftor, was first approved for people with CF and the G551D CFTR mutation. This study describes the long-term clinical effectiveness of ivacaftor in this population. METHODS: We conducted a multicenter, prospective, longitudinal, observational study of people with CF ages ≥6 years with at least one copy of the G551D CFTR mutation. Measurements of lung function, growth, quality of life, and sweat chloride were performed after ivacaftor initiation (baseline, 1 month, 3 months, 6 months, and annually thereafter until 5.5 years). RESULTS: Ninety-six participants were enrolled, with 81% completing all study measures through 5.5 years. This cohort experienced significant improvements in percent predicted forced expiratory volume in 1 second (ppFEV1) of 4.8 [2.6, 7.1] (p < 0.001) at 1.5 years, that diminished to 0.8 [-2.0, 3.6] (p = 0.57) at 5.5 years. Adults experienced larger improvements in ppFEV1 (7.4 [3.6, 11.3], p < 0.001 at 1.5 years and 4.3 [0.6, 8.1], p = 0.02 at 5.5 years) than children (2.8 [0.1, 5.6], p = 0.04 at 1.5 years and -2.0 [-5.9, 2.0], p = 0.32 at 5.5 years). Rate of lung function decline for the overall study cohort from 1 month after ivacaftor initiation through 5.5 years was estimated to be -1.22 pp/year [-1.70, -0.73]. Significant improvements in growth, quality of life measures, sweat chloride, Pseudomonas aeruginosa detection, and pulmonary exacerbation rates requiring antimicrobial therapy persisted through five years of therapy. CONCLUSIONS: These findings demonstrate the long-term benefits and disease modifying effects of ivacaftor in children and adults with CF and the G551D mutation.
BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, ivacaftor, was first approved for people with CF and the G551D CFTR mutation. This study describes the long-term clinical effectiveness of ivacaftor in this population. METHODS: We conducted a multicenter, prospective, longitudinal, observational study of people with CF ages ≥6 years with at least one copy of the G551D CFTR mutation. Measurements of lung function, growth, quality of life, and sweat chloride were performed after ivacaftor initiation (baseline, 1 month, 3 months, 6 months, and annually thereafter until 5.5 years). RESULTS: Ninety-six participants were enrolled, with 81% completing all study measures through 5.5 years. This cohort experienced significant improvements in percent predicted forced expiratory volume in 1 second (ppFEV1) of 4.8 [2.6, 7.1] (p < 0.001) at 1.5 years, that diminished to 0.8 [-2.0, 3.6] (p = 0.57) at 5.5 years. Adults experienced larger improvements in ppFEV1 (7.4 [3.6, 11.3], p < 0.001 at 1.5 years and 4.3 [0.6, 8.1], p = 0.02 at 5.5 years) than children (2.8 [0.1, 5.6], p = 0.04 at 1.5 years and -2.0 [-5.9, 2.0], p = 0.32 at 5.5 years). Rate of lung function decline for the overall study cohort from 1 month after ivacaftor initiation through 5.5 years was estimated to be -1.22 pp/year [-1.70, -0.73]. Significant improvements in growth, quality of life measures, sweat chloride, Pseudomonas aeruginosa detection, and pulmonary exacerbation rates requiring antimicrobial therapy persisted through five years of therapy. CONCLUSIONS: These findings demonstrate the long-term benefits and disease modifying effects of ivacaftor in children and adults with CF and the G551D mutation.
Authors: Michael S Stalvey; Jesse Pace; Minoo Niknian; Mark N Higgins; Valerie Tarn; Joy Davis; Sonya L Heltshe; Steven M Rowe Journal: Pediatrics Date: 2017-02 Impact factor: 7.124
Authors: Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting Journal: Am J Respir Crit Care Med Date: 2019-05-01 Impact factor: 21.405
Authors: Sonya L Heltshe; Steven M Rowe; Michelle Skalland; Arthur Baines; Manu Jain Journal: Am J Respir Crit Care Med Date: 2018-06-01 Impact factor: 21.405
Authors: Nataliya Volkova; Kristin Moy; Jennifer Evans; Daniel Campbell; Simon Tian; Christopher Simard; Mark Higgins; Michael W Konstan; Gregory S Sawicki; Alexander Elbert; Susan C Charman; Bruce C Marshall; Diana Bilton Journal: J Cyst Fibros Date: 2019-06-10 Impact factor: 5.482
Authors: Michael W Konstan; Edward F McKone; Richard B Moss; Gautham Marigowda; Simon Tian; David Waltz; Xiaohong Huang; Barry Lubarsky; Jaime Rubin; Stefanie J Millar; David J Pasta; Nicole Mayer-Hamblett; Christopher H Goss; Wayne Morgan; Gregory S Sawicki Journal: Lancet Respir Med Date: 2016-12-21 Impact factor: 30.700
Authors: Alexandra L Quittner; Gregory S Sawicki; Ann McMullen; Lawrence Rasouliyan; David J Pasta; Ashley Yegin; Michael W Konstan Journal: Qual Life Res Date: 2011-10-14 Impact factor: 4.147
Authors: Leona Bessonova; Nataliya Volkova; Mark Higgins; Leif Bengtsson; Simon Tian; Christopher Simard; Michael W Konstan; Gregory S Sawicki; Ase Sewall; Stephen Nyangoma; Alexander Elbert; Bruce C Marshall; Diana Bilton Journal: Thorax Date: 2018-05-10 Impact factor: 9.139
Authors: Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel Journal: J Cyst Fibros Date: 2022-04-16 Impact factor: 5.527
Authors: Dave P Nichols; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Scott D Sagel; Margaret Rosenfeld; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; Shannon Kirby; Jill M VanDalfsen; John P Clancy; Steven M Rowe Journal: J Cyst Fibros Date: 2021-02-19 Impact factor: 5.482
Authors: Kevin J Scully; Laura T Jay; Steven Freedman; Gregory S Sawicki; Ahmet Uluer; Joel S Finkelstein; Melissa S Putman Journal: Nutrients Date: 2022-01-12 Impact factor: 5.717